<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33097688</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-4889</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>Cell death &amp; disease</Title><ISOAbbreviation>Cell Death Dis</ISOAbbreviation></Journal><ArticleTitle>Aggresome formation and liquid-liquid phase separation independently induce cytoplasmic aggregation of TAR DNA-binding protein 43.</ArticleTitle><Pagination><StartPage>909</StartPage><MedlinePgn>909</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">909</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-020-03116-2</ELocationID><Abstract><AbstractText>Cytoplasmic inclusion of TAR DNA-binding protein 43 (TDP-43) is a pathological hallmark of amyotrophic lateral sclerosis (ALS) and a subtype of frontotemporal lobar degeneration (FTLD). Recent studies have suggested that the formation of cytoplasmic TDP-43 aggregates is dependent on a liquid-liquid phase separation (LLPS) mechanism. However, it is unclear whether TDP-43 pathology is induced through a single intracellular mechanism such as LLPS. To identify intracellular mechanisms responsible for TDP-43 aggregation, we established a TDP-43 aggregation screening system using a cultured neuronal cell line stably expressing EGFP-fused TDP-43 and a mammalian expression library of the inherited ALS/FTLD causative genes, and performed a screening. We found that microtubule-related proteins (MRPs) and RNA-binding proteins (RBPs) co-aggregated with TDP-43. MRPs and RBPs sequestered TDP-43 into the cytoplasmic aggregates through distinct mechanisms, such as microtubules and LLPS, respectively. The MRPs-induced TDP-43 aggregates were co-localized with aggresomal markers and dependent on histone deacetylase 6 (HDAC6), suggesting that aggresome formation induced the co-aggregation. However, the MRPs-induced aggregates were not affected by 1,6-hexanediol, an LLPS inhibitor. On the other hand, the RBPs-induced TDP-43 aggregates were sensitive to 1,6-hexanediol, but not dependent on microtubules or HDAC6. In sporadic ALS patients, approximately half of skein-like TDP-43 inclusions were co-localized with HDAC6, but round and granular type inclusion were not. Moreover, HDAC6-positive and HDAC6-negative inclusions were found in the same ALS patient, suggesting that the two distinct pathways are both involved in TDP-43 pathology. Our findings suggest that at least two distinct pathways (i.e., aggresome formation and LLPS) are involved in inducing the TDP-43 pathologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Seiji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, 464-8601, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inami</LastName><ForeName>Hidekazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, 464-8601, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oiwa</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, 464-8601, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, 464-8601, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakai</LastName><ForeName>Shohei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, 464-8601, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komine</LastName><ForeName>Okiru</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, 464-8601, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, 464-8601, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iguchi</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Koji</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4655-0035</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, 464-8601, Japan. kojiyama@riem.nagoya-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan. kojiyama@riem.nagoya-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Dis</MedlineTA><NlmUniqueID>101524092</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="C433811">HDAC6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D000073864">Histone Deacetylase 6</NameOfSubstance></Chemical><Chemical><RegistryNumber>SH1WY3R615</RegistryNumber><NameOfSubstance UI="D015739">Nocodazole</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073864" MajorTopicYN="N">Histone Deacetylase 6</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059625" MajorTopicYN="N">Liquid-Liquid Extraction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015739" MajorTopicYN="N">Nocodazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>24</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33097688</ArticleId><ArticleId IdType="pmc">PMC7585435</ArticleId><ArticleId IdType="doi">10.1038/s41419-020-03116-2</ArticleId><ArticleId IdType="pii">10.1038/s41419-020-03116-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 2011;13:38&#x2013;50. doi: 10.1038/nrn3121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional significance of TDP-43 mutations in disease. Adv. Genet. 2015;91:1&#x2013;53. doi: 10.1016/bs.adgen.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem. J. 2017;474:1417&#x2013;1438. doi: 10.1042/BCJ20160499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160499</ArticleId><ArticleId IdType="pmc">PMC5639257</ArticleId><ArticleId IdType="pubmed">28389532</ArticleId></ArticleIdList></Reference><Reference><Citation>Courchaine EM, Lu A, Neugebauer KM. Droplet organelles? EMBO J. 2016;35:1603&#x2013;1612. doi: 10.15252/embj.201593517.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201593517</ArticleId><ArticleId IdType="pmc">PMC4969579</ArticleId><ArticleId IdType="pubmed">27357569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman AA, Weber CA, Julicher F. Liquid-liquid phase separation in biology. Annu. Rev. Cell. Dev. Biol. 2014;30:39&#x2013;58. doi: 10.1146/annurev-cellbio-100913-013325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100913-013325</ArticleId><ArticleId IdType="pubmed">25288112</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Na Z, Slavoff SA. P-bodies: composition, properties, and functions. Biochemistry. 2018;57:2424&#x2013;2431. doi: 10.1021/acs.biochem.7b01162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.7b01162</ArticleId><ArticleId IdType="pmc">PMC6296482</ArticleId><ArticleId IdType="pubmed">29381060</ArticleId></ArticleIdList></Reference><Reference><Citation>Protter DSW, Parker R. Principles and properties of stress granules. Trends Cell Biol. 2016;26:668&#x2013;679. doi: 10.1016/j.tcb.2016.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2016.05.004</ArticleId><ArticleId IdType="pmc">PMC4993645</ArticleId><ArticleId IdType="pubmed">27289443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat. Rev. Neurosci. 2019;20:649&#x2013;666. doi: 10.1038/s41583-019-0222-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-019-0222-5</ArticleId><ArticleId IdType="pmc">PMC6986315</ArticleId><ArticleId IdType="pubmed">31582840</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, Chen X, Wu X, Zhang M. Formation of biological condensates via phase separation: characteristics, analytical methods, and physiological implications. J. Biol. Chem. 2019;294:14823&#x2013;14835. doi: 10.1074/jbc.REV119.007895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.REV119.007895</ArticleId><ArticleId IdType="pmc">PMC6779427</ArticleId><ArticleId IdType="pubmed">31444270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateju D, et al. An aberrant phase transition of stress granules triggered by misfolded protein and prevented by chaperone function. EMBO J. 2017;36:1669&#x2013;1687. doi: 10.15252/embj.201695957.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201695957</ArticleId><ArticleId IdType="pmc">PMC5470046</ArticleId><ArticleId IdType="pubmed">28377462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognesi B, et al. A concentration-dependent liquid phase separation can cause toxicity upon increased protein expression. Cell Rep. 2016;16:222&#x2013;231. doi: 10.1016/j.celrep.2016.05.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.05.076</ArticleId><ArticleId IdType="pmc">PMC4929146</ArticleId><ArticleId IdType="pubmed">27320918</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakawa K, Handa H, Kawakami K. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons. Nat. Commun. 2020;11:1004. doi: 10.1038/s41467-020-14815-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14815-x</ArticleId><ArticleId IdType="pmc">PMC7035286</ArticleId><ArticleId IdType="pubmed">32081878</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102:321&#x2013;338. doi: 10.1016/j.neuron.2019.01.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.048</ArticleId><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142:1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777&#x2013;794. doi: 10.1007/s00401-013-1125-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1125-6</ArticleId><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Hayakawa T, Wakasugi K, Yamanaka K. Cystatin C protects neuronal cells against mutant copper-zinc superoxide dismutase-mediated toxicity. Cell Death Dis. 2014;5:e1497. doi: 10.1038/cddis.2014.459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.459</ArticleId><ArticleId IdType="pmc">PMC4237269</ArticleId><ArticleId IdType="pubmed">25356866</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Kaneko K, Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J. Biol. Chem. 2013;288:3641&#x2013;3654. doi: 10.1074/jbc.M112.433615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433615</ArticleId><ArticleId IdType="pmc">PMC3561582</ArticleId><ArticleId IdType="pubmed">23235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Motohashi K. A simple and efficient seamless DNA cloning method using SLiCE from Escherichia coli laboratory strains and its application to SLiP site-directed mutagenesis. BMC Biotechnol. 2015;15:47. doi: 10.1186/s12896-015-0162-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12896-015-0162-8</ArticleId><ArticleId IdType="pmc">PMC4453199</ArticleId><ArticleId IdType="pubmed">26037246</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishino K, et al. Mice deficient in the C-terminal domain of TAR DNA-binding protein 43 develop age-dependent motor dysfunction associated with impaired Notch1-Akt signaling pathway. Acta Neuropathol. Commun. 2019;7:118. doi: 10.1186/s40478-019-0776-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0776-5</ArticleId><ArticleId IdType="pmc">PMC6657153</ArticleId><ArticleId IdType="pubmed">31345270</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray DT, et al. Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains. Cell. 2017;171:615&#x2013;627. doi: 10.1016/j.cell.2017.08.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.08.048</ArticleId><ArticleId IdType="pmc">PMC5650524</ArticleId><ArticleId IdType="pubmed">28942918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017;95:808&#x2013;816. doi: 10.1016/j.neuron.2017.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.025</ArticleId><ArticleId IdType="pmc">PMC5576574</ArticleId><ArticleId IdType="pubmed">28817800</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 1998;143:1883&#x2013;1898. doi: 10.1083/jcb.143.7.1883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.143.7.1883</ArticleId><ArticleId IdType="pmc">PMC2175217</ArticleId><ArticleId IdType="pubmed">9864362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J. 2009;23:451&#x2013;463. doi: 10.1096/fj.08-117614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-117614</ArticleId><ArticleId IdType="pmc">PMC2630789</ArticleId><ArticleId IdType="pubmed">18854435</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawaguchi Y, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727&#x2013;738. doi: 10.1016/S0092-8674(03)00939-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00939-5</ArticleId><ArticleId IdType="pubmed">14675537</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 2005;280:40282&#x2013;40292. doi: 10.1074/jbc.M508786200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508786200</ArticleId><ArticleId IdType="pubmed">16192271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Sheng S, Qin C. The role of HDAC6 in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2013;33:283&#x2013;295. doi: 10.3233/JAD-2012-120727.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120727</ArticleId><ArticleId IdType="pubmed">22936009</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE. 2010;5:e13250. doi: 10.1371/journal.pone.0013250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013250</ArticleId><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, et al. Characteristic features of FUS inclusions in spinal motor neurons of sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2020;79:370&#x2013;377. doi: 10.1093/jnen/nlaa003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlaa003</ArticleId><ArticleId IdType="pubmed">32142134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Cohen TJ. Aggregation of the nucleic acid-binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation. J. Biol. Chem. 2019;294:3696&#x2013;3706. doi: 10.1074/jbc.RA118.006351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.006351</ArticleId><ArticleId IdType="pmc">PMC6416430</ArticleId><ArticleId IdType="pubmed">30630951</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, et al. Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Acta Neuropathol. Commun. 2017;5:96. doi: 10.1186/s40478-017-0493-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0493-x</ArticleId><ArticleId IdType="pmc">PMC5719900</ArticleId><ArticleId IdType="pubmed">29216908</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharana S, et al. RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science. 2018;360:918&#x2013;921. doi: 10.1126/science.aar7366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aar7366</ArticleId><ArticleId IdType="pmc">PMC6091854</ArticleId><ArticleId IdType="pubmed">29650702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lim L, Lu Y, Song J. A unified mechanism for LLPS of ALS/FTLD-causing FUS as well as its modulation by ATP and oligonucleic acids. PLoS Biol. 2019;17:e3000327. doi: 10.1371/journal.pbio.3000327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000327</ArticleId><ArticleId IdType="pmc">PMC6590835</ArticleId><ArticleId IdType="pubmed">31188823</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter-Landsberg C, Leyk J. Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration. Acta Neuropathol. 2013;126:793&#x2013;807. doi: 10.1007/s00401-013-1158-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1158-x</ArticleId><ArticleId IdType="pubmed">23912309</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Nonaka T, Suzuki G, Kametani F, Hasegawa M. Gain-of-function profilin 1 mutations linked to familial amyotrophic lateral sclerosis cause seed-dependent intracellular TDP-43 aggregation. Hum. Mol. Genet. 2016;25:1420&#x2013;1433. doi: 10.1093/hmg/ddw024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw024</ArticleId><ArticleId IdType="pubmed">26908597</ArticleId></ArticleIdList></Reference><Reference><Citation>Taes I, et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum. Mol. Genet. 2013;22:1783&#x2013;1790. doi: 10.1093/hmg/ddt028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt028</ArticleId><ArticleId IdType="pubmed">23364049</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, Wang H, Zhang Y, Ying Z, Wang G. Loss of TDP-43 inhibits amyotrophic lateral sclerosis-linked mutant SOD1 aggresome formation in an HDAC6-dependent manner. J. Alzheimers Dis. 2015;45:373&#x2013;386. doi: 10.3233/JAD-142244.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-142244</ArticleId><ArticleId IdType="pubmed">25720411</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SM, et al. TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Brain Commun. 2019;1:fcz014. doi: 10.1093/braincomms/fcz014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcz014</ArticleId><ArticleId IdType="pmc">PMC6788139</ArticleId><ArticleId IdType="pubmed">31633109</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamphlett, R., Luquin, N., McLean, C., Kum Jew, S. &amp; Adams, L. TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with or without mutations. Neuropathol. Appl. Neurobiol.35, 222&#x2013;225 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18986339</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin, V. M. et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol.7, 409&#x2013;416 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoseki, A. et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann. Neurol.63, 538&#x2013;542 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18438952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski, T. J. et al. Mutations in the FUS/TLS Gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science323, 1205&#x2013;1208 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science323, 1208&#x2013;1211 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. J. et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature495, 467&#x2013;473 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, J. O. et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci.17, 664&#x2013;666 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada, M. et al. Matrin 3 is a component of neuronal cytoplasmic inclusions of motor neurons in sporadic amyotrophic lateral sclerosis. Am. J. Pathol.188, 507&#x2013;514 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29128563</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns, N. J. et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol.171, 227&#x2013;240 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J. Neuropathol. Exp. Neurol.66, 152&#x2013;157 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho, M. A. et al. VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. J. Biol. Chem.284, 12384&#x2013;12398 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673306</ArticleId><ArticleId IdType="pubmed">19237541</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, H. X. et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature477, 211&#x2013;215 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, K. L. et al. (2012) UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol. Aging33, 2527.e3&#x2013;2527.e10 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22717235</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahed, A. C. et al. UBQLN2 mutation causing heterogeneous X-linked dominant neurodegeneration. Ann. Neurol.75, 793&#x2013;798 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106259</ArticleId><ArticleId IdType="pubmed">24771548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs, G. G. et al. Clinicopathological description of two cases with gene mutation associated with frontotemporal dementia. Neuropathology36, 27&#x2013;38 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26234378</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt, A. et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci.18, 631&#x2013;636 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck, I. et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology15, 2116&#x2013;2125 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691687</ArticleId><ArticleId IdType="pubmed">26581300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, C. H. et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature488, 499&#x2013;503 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, B. N. et al. Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiol. Aging36, 1602.e17&#x2013;1602.e27 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357530</ArticleId><ArticleId IdType="pubmed">25499087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>